

ReVEAL

Fuchs' Corneal Endothelial Dystrophy



A randomized, double-masked, vehicle-controlled, paired-eye study to evaluate the safety, tolerability and efficacy of 12 weeks' treatment with twice-daily topical eye drop formulation of elamipretide to treat patients with Fuchs' corneal endothelial dystrophy (FCED).

~15,000

CORNEAL TRANSPLANTS EACH YEAR ARE RELATED TO FCED

The trial will assess ~25 patients with mild to moderate corneal edema




TRIAL DURATION: 12 WEEKS



TRIAL BEGAN
Q1 2016

TRIAL SITES



- 1 Boston, Massachusetts
MICHAEL B. RAIZMAN, MD
- 2 Cincinnati, Ohio
EDWARD HOLLAND, MD

ENDPOINTS

PRIMARY

Safety and tolerability

SECONDARY

Reduction in central corneal thickness, improved visual acuity and change in endothelial cell count and shape